Extended indication Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
Therapeutic value No judgement
Total cost 53,700.00
Registration phase Clinical trials

Product

Active substance Dapagliflozine
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension
Main indication Diabetes
Extended indication Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
Proprietary name Forxiga
Manufacturer AstraZeneca
Mechanism of action SGLT inhibitor
Route of administration Oral
Therapeutical formulation Film-coated tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date December 2020
Expected Registration September 2021
Registration phase Clinical trials
Additional comments Fabrikant verwacht registratie in Q2/Q3 2021.

Therapeutic value

Therapeutic value No judgement
Substantiation Op dit moment zijn er niet veel patiënten in Nederland in deze leeftijdsgroep die in aanmerking zullen komen voor dapagliflozine.
Duration of treatment continuous
Frequency of administration 1 times a day
Dosage per administration 5mg
References NCT03199053

Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.

References Baan CA, Poos MJJC. Hoe vaak komt diabetes mellitus voor en hoeveel mensen sterven eraan? In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, 2013.; Diabetes vereniging Nederland;
Additional comments Het overgrote deel (ongeveer 98%) van de kinderen heeft DM type 1. Het aantal kinderen met DM type 2 is de laatste jaren toegenomen. Ongeveer 12.000 kinderen en jongvolwassenen hebben diabetes. Dit betekent dat er maximaal 240 patiënten in Nederland DM type 2 hebben. Naar verwachting zal deze behandeling bij maximaal 100 patiënten ingezet worden.

Expected cost per patient per year

Cost 537.00
References medicijnkosten;
Additional comments FORXIGA TABLET FILMOMHULD 5 MG 1dd dus 365,25*1,47= €537

Potential total cost per year

Total cost

53,700.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Renal failure
References adisinsight
Additional comments Lopende fase 3 studie

Other information

There is currently no futher information available.